TICKERNERD
Menu
MTVAMTVAHealthcare · Biotechnology

MTVA Stock Forecast: MetaVia, Inc. Price Predictions for 2026-2027

Last close, 13 Oct 2026
$1.43
−1.38% on the day

The 2 Wall Street analysts covering MetaVia, Inc. hold a median 12-month price target of $20 — +1298.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 12 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$9.6M
Ticker Nerd rank
17 / 100
Median analyst target
$20
Analysts covering
2
Revenue$0.0
Operating income−$5.4M
Net income−$5.3M
Free cash flow−$3.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
−13.9%
YTD
−83.0%
1Y
−86.9%
From 52W high
−88.1%
From 52W low
+47.4%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MTVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MetaVia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Growth
50
Accruals
48
Revisions
39
Momentum
24
Quality
20
Issuance
15
Volatility
12
Value
6

Size (92): Smaller than most of the companies we track.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MTVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MTVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Jan 26Apr 26Jul 26Oct 26MTVAHigh $30Median $20Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $8Median $20High $30

The green dot is the last close — the median target sits +1298.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 July 2026HC Wainwright & Co.ReiteratesBuy$20
18 May 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026HC Wainwright & Co.MaintainsBuy—
6 Jan 2026HC Wainwright & Co.MaintainsBuy—
4 Sept 2025HC Wainwright & Co.AssumesBuy$12
19 May 2025Maxim GroupMaintainsBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MTVA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MTVA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Oct 2026, MetaVia, Inc. returned −86.9% against +18.6% for the S&P 500, dividends included.

MTVA vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26MTVAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MTVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

MetaVia, Inc. (MTVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−175.7%

Higher than 8% of US stocks

Return on assets
−58.8%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MetaVia, Inc. (MTVA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MetaVia, Inc. has a market value of $9.6M and an enterprise value of −$2.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$14.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.8M.

  • Shares outstanding: 5.2M.

  • Trailing P/E: −0.2×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • MetaVia, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

MTVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MTVAMetaVia, Inc.$9.6M
17
GDTCCytoMed Therapeutics Ltd.$9.6M
29
LSTALisata Therapeutics, Inc.$9.5M
56
NIKINiki Biosolutions, Inc.$9.4M
12
SNTISenti Biosciences Holdings, Inc.$9.9M
61
ADILAdial Pharmaceuticals, Inc.$9.2M
21
VTGNVistagen Therapeutics, Inc.$10.1M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MetaVia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MTVA news & analysis

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

PRNewsWire · 13 Oct 2026positive

MetaVia announced the appointment of Sarah Browne, M.D., as chief medical officer. The company said she has experience leading liver and metabolic disease drug development programs, including MASH, and advancing therapies through Phase 2 and into Phase 3.

Why it matters — The appointment adds clinical-development leadership with experience in areas relevant to MetaVia’s cardiometabolic focus, including dual GLP-1/glucagon receptor agonist development.

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

PRNewsWire · 9 Sept 2026positive

MetaVia announced results from a preclinical tissue distribution study of DA-1726 showing that, after subcutaneous administration, radioactivity was slowly absorbed and broadly distributed throughout the body, with the highest exposure observed in adipose (fat) tissue and prolonged retention consistent with its once-weekly dosing profile. The findings provide mechanistic support for the drug candidate's differentiated waist circumference reduction profile.

Why it matters — MTVA watchers would care because the results offer preclinical evidence supporting the biological rationale and differentiated mechanism behind DA-1726's potential waist circumference reduction, a key focus of the company's clinical-stage pipeline.

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRNewsWire · 6 Aug 2026positive

MetaVia Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update. The company announced that all active patients in the ongoing Phase 1 Part 3 study of DA-1726 successfully reached the highest planned dose levels of 48 mg and 64 mg, with 16-week topline data expected in the fourth quarter of 2026.

Why it matters — A MetaVia watcher would care because this update signals clinical progress for DA-1726, with all active patients achieving target dose levels and key topline data anticipated in the fourth quarter of 2026.

FAQ

Frequently asked questions about MTVA stock

What is the MTVA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering MetaVia, Inc. have a median 12-month price target of $20, with estimates ranging from $8 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MTVA stock a buy right now?

Of the 2 analysts covering MetaVia, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MetaVia, Inc. 17 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MTVA?

As at 12 Oct 2026, MetaVia, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will MTVA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1298.6% from the last close, and Ticker Nerd's factor model ranks MetaVia, Inc. 17 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MTVA stock forecast for 2030?

No analyst covering MetaVia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $30 over the next 12 months.

How has MTVA stock performed over the past year?

MetaVia, Inc. returned -86.9% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MetaVia, Inc. do?

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic diseases.

What is the latest news on MTVA?

The most recent item we track (PRNewsWire, 13 Oct 2026): "MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer". MetaVia announced the appointment of Sarah Browne, M.D., as chief medical officer. The company said she has experience leading liver and metabolic disease drug development programs, including MASH, and advancing therapies through Phase 2 and into Phase 3.

Company

About MetaVia, Inc.

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic diseases. The company’s current programs center on obesity and metabolic dysfunction-associated steatohepatitis (MASH), with an emphasis on drug candidates designed to address metabolic regulation, appetite control, and related disease pathways. MetaVia’s pipeline also includes research in type 2 diabetes and other cardiometabolic conditions, reflecting its broader focus on diseases linked to metabolic dysfunction. Based in Cambridge, Massachusetts, MetaVia operates in the biopharmaceutical sector, where its role is to advance early- and mid-stage drug development through clinical testing and therapeutic innovation.

CEO Mr. Hyung Heon Kim · 8 employees · United States · https://www.metaviatx.com